Mark Avagliano, Chief Business Officer at G1 Therapeutics, Inc. (GTHX), sold 1,445 shares at $10.61 ($15K) on 2022-01-05, disclosed to the SEC on 2022-01-05.
Open-market sale of $15k GTHX by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| GTHX | SELL | 2024-01-08 | $13K | — | Filing → |